December 11, 2015 7:24am
You get a real feel for a market just after the open …
The vibe is very altering when filled with volatility and volume stimulating day’s ranges as traders and speculators prep for any or the next coming of algorithmic programs to define the session.
Subscribe or take your losses without complaining …
Critical information ahead of “our” universe’s open!
Reporting form Atlanta, GE … The 2015 World Stem Cell Summit and RegMed Capital Conference.
DOW futures are DOWN -0.9% and NASDAQ futures are DOWN -0.08%
U.S. stock index futures indicated a broadly lower open on Friday as traders looked towards the release of a set of data that will provide one last look at the mood of consumers before Federal Reserve officials meet next week to consider the first rate hike in nine years.
- Dow futures fell more than 150 points ahead of the release of some key data points.
European markets extended losses on Friday as sentiment is damaged by yet more declines in oil prices.
The pan-European STOXX 600 was down over 1.5 percent with all major indices in negative territory.
Asian markets traded mostly lower on Friday, despite Wall Street's positive finish overnight, as record low oil prices weighed resources plays and China shares traded in negative territory as another top executive was reported missing by local media.
Data docket: Retail sales and PPI are due at 8:30 a.m. ET, with business inventories and consumer sentiment scheduled for release at 10:00 a.m.
The RegMed sector closed NEGATIVE on Thursday and Wednesday after a POSITIVE close on Tuesday and a NEGATIVE close on Monday.
Thursday closed NEGATIVE with 21 decliners, 20 advancers and 2 flats following Wednesday’s NEGATIVE close with 31 decliners, 10 advancers and 2 flats after Tuesday’s POSITIVE close with 16 decliners, 25 advances and 2 flats post Monday’s NEGATIVE close with 40 decliners, 3 advancers and 0 flat.
Having the courage to go against consensus and against the market requires drinking more liquor in reporting or projecting a day’s happenings.
- I try to justify my predictions and analysis based on patterns that are multiple in perspective but, singular in purpose.
I am not in the business of winning corporate finance business but, protecting the assets of investors!
Friday’s indications:
- bluebird bio (BLUE) closed UP +$5.22 to $61.75 which was up +$0.25 in the aftermarket. The risk-to-reward ratio for BLUE’s stock has shifted in favor of buyers now that its market cap is just $2.26 billion. Maintaining BUY;
- Capricor (CAPR) closed UP +$0.164 after Wednesday’s +$0.18 to $4.03 <still under $10.25 on March 18, 2015> on small 11.87 share volume <3 month average = 21.8 K shares>. The times I have said sell out way the buy daily actions. Maintaining SELL;
- With a deadline fast approaching for shareholders of Ocata Therapeutics (OCAT) trading at $8.48 to endorse a potential sale to Astellas Pharma, at least one investor is predicting a solid block of stock owners — holding at least 28% of OCAT's shares — will not agree to the deal as is. Read … http://www.bizjournals.com/boston/blog/bioflash/2015/12/ocata-investor-says-opposition-to-astellas-buyout.html?ana=yahoo
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
